Rivfloza Injection, Solution
Product Images NDC 0169-5308

Product Visual Gallery

This gallery contains 50 technical images submitted to the FDA as part of the official labeling for Rivfloza (NDC 0169-5308). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novo Nordisk, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image_47 (Export 00)

RIVFLOZA 80 mg/0.5 mL injection solution for subcutaneous use. The label shows a clear vial with a blue cap and specifies that the 80 mg dose is intended for children aged 9 to 11 years weighing less than 110 pounds (50 kilograms). Manufactured by Novo Nordisk.*

FDA Label Image

Image_46 (Export 01)

FDA Label Image

Image_45 (Export 02)

FDA Label Image

Image_44 (Export 03)

FDA Label Image

Image_43 (Export 04)

An instructional diagram showing a hand disposing of used syringes into a sharps disposal container. The image highlights safe disposal by placing syringes vertically into the container's opening.*

FDA Label Image

Image_42 (Export 05)

An instructional illustration showing the subcutaneous injection technique using a syringe. The top panel depicts a hand injecting medication into the abdomen at a 45-degree angle. The bottom panel shows a hand pressing a cotton ball against the injection site after the injection.*

FDA Label Image

Image_41 (Export 06)

Illustration showing the correct technique for subcutaneous injection using a syringe with a plunger rod and rubber stopper, demonstrating the injection angle at 45 degrees.*

FDA Label Image

Image_40 (Export 07)

An instructional illustration showing a hand holding a syringe at a 45-degree angle, ready to inject subcutaneously into the skin of another hand's finger. This diagram demonstrates the proper injection angle for subcutaneous administration.*

FDA Label Image

Image_39 (Export 08)

Illustration showing a needle attached to a syringe positioned above a vial, with a green upward arrow indicating the needle is to be inserted or removed from the vial. The image appears instructional, related to the use of the injection solution RIVFLOZA (nedosiran).*

FDA Label Image

Image_38 (Export 09)

An instructional illustration showing hands preparing a syringe for injection. The syringe is attached to a vial, with the plunger being drawn back to fill the syringe with medication. The image indicates the injection preparation process likely for the subcutaneous injection of RIVFLOZA (nedosiran).*

FDA Label Image

Image_37 (Export 10)

Two-panel instructional illustration showing preparation steps for RIVFLOZA (nedosiran) injection. The top panel depicts a syringe needle inserting through the rubber stopper of a vial, indicating medication withdrawal. The bottom panel illustrates a hand holding the vial with the needle inside, pushing down the syringe plunger. An arrow indicates the downward motion of the plunger, and a note advises to keep the needle tip in the medicine.*

FDA Label Image

Image_36 (Export 11)

Instructional diagram showing two hands removing the cap from a syringe needle with double-headed arrows indicating the cap is being pulled straight off. This image is likely part of usage instructions for RIVFLOZA, an injection solution containing nedosiran.*

FDA Label Image

Image_34 (Export 12)

An instructional illustration showing a hand gripping a vial or small bottle with a blue cap. A green arrow curves leftward above the hand, indicating a twisting or turning motion to remove the cap.*

FDA Label Image

Image_33 (Export 13)

An instructional illustration showing a hand holding a small rectangular alcohol prep pad, wiping an area on the skin, likely demonstrating skin preparation before a subcutaneous injection.*

FDA Label Image

Image_32 (Export 14)

An illustration showing recommended injection sites for RIVFLOZA (nedosiran) solution. The diagram highlights the stomach area and upper thighs in blue as the preferred subcutaneous injection locations on a frontal view of a human figure.*

FDA Label Image

Image_31 (Export 15)

A diagram showing a vial with a blue cap containing a liquid that ranges in color from colorless to yellow, illustrating the expected appearance of the solution.*

FDA Label Image

Image_30 (Export 16)

An instructional illustration showing a hand lifting a vial or small bottle from a box or packaging. The image is likely part of usage instructions for a subcutaneous injection product.*

FDA Label Image

Image_29 (Export 17)

An instructional illustration showing a rectangular box with a callout pointing to the location for the expiration date labeled as 'EXP YYYY-MM-DD.' Another part of the image depicts the box placed on a surface with a clock indicating to wait for 30 minutes, suggesting a preparation or acclimation step before use.*

FDA Label Image

Image_28 (Export 18)

An instructional illustration showing three items typically used in subcutaneous injection procedures: alcohol wipes for skin cleansing, cotton balls or gauze for applying pressure or cleaning, and a red sharps disposal container for safe disposal of needles and other sharp objects.*

FDA Label Image

Image_27 (Export 19)

An instructional illustration showing two 1 mL syringes each equipped with a 27-gauge, ½-inch needle. The components labeled include the needle cap, barrel, rubber stopper, finger grip, and plunger rod.*

FDA Label Image

Image_26 (Export 20)

An instructional illustration showing three items used for injection procedures: alcohol wipes in a packet, cotton balls or gauze depicted as a rounded clump, and a red sharps disposal container with a lid for safely discarding needles and syringes.*

FDA Label Image

Image_25 (Export 21)

An instructional illustration showing RIVFLOZA vial(s) and parts of a syringe. The vial is labeled as RIVFLOZA, available as one or two vials per carton. The syringe components illustrated include needle cap, barrel, rubber stopper, finger grip, and plunger rod. It also indicates the use of one or two 1 mL syringes with an attached 27-gauge ½-inch needle.*

FDA Label Image

Image_24 (Export 22)

RIVFLOZA 80 mg/0.5 mL injection, solution for subcutaneous use, presented with a small clear vial with a blue cap. The label notes use for children 9 to 11 years of age weighing less than 110 pounds (50 kilograms). Manufactured by Novo Nordisk.*

FDA Label Image

Image_23 (Export 23)

An instructional diagram showing dosage guidelines for RIVFLOZA (nedosiran) injection solution. It presents two dosage strengths: 128 mg/0.8 mL for patients 12 years and older weighing under 110 lbs (50 kg), and 160 mg/mL for patients 9 years and older weighing 110 lbs (50 kg) or more.*

FDA Label Image

Image_22 (Export 24)

FDA Label Image

Image_21 (Export 25)

FDA Label Image

Image_20 (Export 26)

FDA Label Image

Image_19 (Export 27)

An instructional illustration showing a hand disposing of a syringe into a red sharps disposal container. The container is labeled "Sharps disposal container." This diagram depicts safe disposal practices for used injection equipment.*

FDA Label Image

Image_18 (Export 28)

Instructional illustration showing subcutaneous injection technique. The upper image depicts a hand holding a syringe at a 45-degree angle aimed at the outer thigh. The lower image shows a hand applying a cotton ball to the injection site, demonstrating post-injection care.*

FDA Label Image

Image_17 (Export 29)

Illustration showing a hand holding a syringe labeled with the parts 'Plunger Rod' and 'Rubber Stopper.' The syringe is positioned at a 45-degree angle, demonstrating correct handling or injection technique for a subcutaneous injection.*

FDA Label Image

Image_16 (Export 30)

Illustration showing how to hold the RIVFLOZA injection device. It depicts a hand gripping the injection at a 45-degree angle with the other hand preparing a finger for subcutaneous injection, emphasizing the finger grip area on the device.*

FDA Label Image

Image_15 (Export 31)

An instructional illustration showing two hands removing a protective cap from a syringe. An arrow points left to the cap with the text 'Throw cap away' and an arrow points right to the syringe indicating the action of pulling the cap off. No branding or additional text is visible.*

FDA Label Image

Image_14 (Export 32)

An illustration showing a hand applying a small adhesive patch or pad onto the skin, likely as part of a step in administering a subcutaneous injection. The image focuses on the hand and the area of skin where the patch is being placed.*

FDA Label Image

Image_13 (Export 33)

An illustration showing the recommended subcutaneous injection sites for RIVFLOZA (nedosiran). The highlighted areas include the stomach region around the belly button and the upper thighs on both legs.*

FDA Label Image

Image_12 (Export 34)

An illustration of a prefilled syringe labeled "Rivfloza (nedosiran) monthly injection" intended for subcutaneous injection only. The syringe shows the solution color can range from colorless to yellow, with an arrow pointing to the liquid inside the syringe barrel.*

FDA Label Image

Image_11 (Export 35)

An instructional illustration showing a hand gripping the barrel of a syringe, with a large green arrow pointing upward, indicating the direction to pull the syringe out of a packaging tray.*

FDA Label Image

Image_10 (Export 36)

An instructional illustration depicting a box on a flat surface with a clock showing 30 minutes highlighted in yellow, likely indicating a waiting or preparation time of 30 minutes.*

FDA Label Image

Image_09 (Export 37)

An illustration showing a carton box with a pull tab and a label area that indicates the expiration date format as 'EXP YYYY-MM-DD'. This likely represents where the expiration date is printed on the RIVFLOZA injection carton packaging.*

FDA Label Image

Image_08 (Export 38)

An instructional diagram showing three items used for injection site aftercare: an alcohol wipe, cotton balls or gauze, and a sharps disposal container. Each item is illustrated with a black outline and labeled in black text beneath the image.*

FDA Label Image

Image_07 (Export 39)

An instructional diagram showing the parts of a RIVFLOZA (nedosiran) injection, solution for subcutaneous use. The image labels the needle cap removed, barrel, finger grip, and plunger rod of the prefilled injection device.*

FDA Label Image

Image_06 (Export 40)

Illustration diagram of a RIVFLOZA (nedosiran) prefilled injection pen for subcutaneous use, labeling and identifying key parts: needle cap, barrel, finger grip, and plunger rod.*

FDA Label Image

Image_04 (Export 41)

An instructional illustration of the RIVFLOZA injection, 160 mg/mL, showing labeled parts of the prefilled syringe for subcutaneous use. Labels identify the needle cap, medicine in barrel, rubber stopper, finger grip, and plunger rod.*

FDA Label Image

Image_03 (Export 42)

An instructional diagram of a RIVFLOZA 128 mg/0.8 mL subcutaneous injection syringe. The image labels parts of the syringe including the needle cap, medicine in barrel, rubber stopper, finger grip, and plunger rod.*

FDA Label Image

Figure_1 (Figure 1)

A line chart depicting percent change from baseline over study visits from baseline to day 180. Two treatment groups are compared: RIVFLOZA (N=23) represented by a solid line with diamond markers, showing a decreasing trend in percent change, and placebo (N=12) represented by a dashed line with square markers, showing values fluctuating around zero. Error bars indicate variability at each time point.*

FDA Label Image

Image_05 (Image 01)

An instructional illustration showing a RIVFLOZA pre-filled syringe for subcutaneous injection, labeled with the drug name nedosiran. The image also includes icons for an alcohol wipe, cotton balls or gauze, and a sharps disposal container, indicating required supplies for the injection process.*

FDA Label Image

Image_35 (Image 02)

An instructional illustration showing a hand placing a small patch or label on the top of a vial with a rubber stopper, likely demonstrating a step in preparing a subcutaneous injection or medication vial handling.*

FDA Label Image

Sleeve_128mg (Sleeve 128mg)

The image shows the packaging label for Rivfloza (nedosiran) injection, 128 mg/0.8 mL, a subcutaneous injection. The label indicates the product is a sterile single-dose pre-filled syringe with a quantity of 0.8 mL. It is manufactured by Pyramid Laboratories for Dicerna Pharmaceuticals, a Novo Nordisk company, and distributed by Novo Nordisk Inc.*

FDA Label Image

Sleeve_160mg (Sleeve 160mg)

Packaging label for Rivfloza (nedosiran) injection 160 mg/mL by Dicerna, a Novo Nordisk company. The label indicates a 1 mL sterile single-dose pre-filled syringe for subcutaneous injection only. It includes usage warnings and storage instructions, as well as distributor information for Novo Nordisk.*

FDA Label Image

Sleeve_80mg (Sleeve 80mg)

Rivfloza (nedosiran) injection 80 mg/0.5 mL subcutaneous injection vial packaging label. The label shows the product name, strength, dosage form as injection solution, subcutaneous route, and contains dosing instructions, warnings, and manufacturing details. It is labeled Rx only and manufactured by Dicerna, a Novo Nordisk company.*

FDA Label Image

Structural_formula (Structural Formula)

Chemical structure diagram showing the sense (passenger) and antisense (guide) strands of a nucleotide sequence. The diagram includes detailed chemical structures for various nucleotide components and modifications labeled with abbreviations such as Af, Gf, Cf, and AdemA, illustrating the molecular composition relevant to the active ingredient nedosiran in RIVFLOZA injection.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.